Prostate Cancer

Atish D. Choudhury, MD, PhD, discusses clinical trials of interest examining different agents, such as darolutamide, enzalutamide, and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

Jennifer Cullen, MPH, PhD, discusses the genomic test as a predictor of outcomes in patients with unfavorable intermediate-risk prostate cancer and next steps for research.

The addition of enzalutamide to androgen deprivation therapy (ADT) led to maintained health-related quality of life and low symptom burden versus placebo and ADT in men with metastatic castration-sensitive prostate cancer.

Atish D. Choudhury, MD, PhD, discusses antiandrogen treatment selection in nonmetastatic castration-resistant prostate cancer.

Huma Q. Rana, MD, MPH, discusses a recent trial aimed to identify how genetic counseling could impact an individual’s decision to undergo genetic testing and ultimately, identify strategies to improve access to this service for men with potentially lethal prostate cancer.

Findings from the phase 3 STAMPEDE, LATITUDE , and TITAN studies, brought to light the utility of second-generation androgen receptor inhibitors.

Paul L. Nguyen, MD, discusses the role of radiation therapy in high-risk prostate cancer.

Rucaparib (Rubraca) demonstrated encouraging antitumor activity with a manageable safety profile in patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study.

Quoc-Dien Trinh, MD, discusses ​the challenges of the novel coronavirus disease 2019 pandemic in prostate cancer. 

Quoc-Dien Trinh, MD, discusses surgical considerations for patients with prostate cancer in light of the novel coronavirus disease pandemic.

Bradley A. McGregor, MD, sheds light on recently approved agents, as well as a multitude of novel therapies on the horizon, that appear to spell out a promising future for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

The FDA has placed a clinical hold on the phase 1 P-PSMA-101-001 trial examining the autologous CAR T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

Quoc-Dien Trinh, MD, discusses the impact of the COVID-19 pandemic on prostate cancer treatment and factors that are considered to inform treatment decisions.

Cell-free DNA–based androgen receptor locus alterations and enhancers correlated with metastatic prostate cancers determined to be resistant to AR-targeted therapies.

Luteinizing hormone-releasing hormone agonists were found to often be administered later than the scheduled dosing used in patients with prostate cancer on pivotal clinical trials, leading to late testosterone values being greater than 20 ng/dL and the mean testosterone level almost doubling castration level.

In prostate cancer, investigators have revealed a link between disease progression and the severity of splicing dysregulation, as well as establishing intron retention as an indicator of prostate cancer stemness and aggressiveness.

The PARP inhibitor olaparib is now available for patients with metastatic castration-resistant prostate cancer whose tumors harbor mutations in homologous recombination repair genes.

Atish D. Choudhury, MD, PhD, sheds light on the nonmetastatic castration-resistant prostate cancer treatment landscape and notable ongoing trials examining antiandrogens in different settings.

Numerous analyses conducted over the past few years have underscored a serious issue in clinical cancer trials that needs to be addressed: a lack of racial and ethnic diversity among participants.

Paul L. Nguyen, MD, discusses the role of radiation in high-risk prostate cancer and ongoing research efforts in the space.

Rana R. McKay, MD, discusses the benefit of intense neoadjuvant hormone therapy prior to radical prostatectomy in men with high-risk prostate cancer and next steps for research.

Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Neal D. Shore, MD, FACS, discusses challenges with androgen deprivation therapy in recurrent prostate cancer.

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Neal D. Shore, MD, FACS, discusses unique challenges in nonmetastatic castration-resistant prostate cancer.

Michael J. Morris, MD, discusses next steps for prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Fred Saad, MD, FRCS, discusses the impact of apalutamide on nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN trial.

Neal D. Shore, MD, FACS, discusses the cardio-oncology strategies that can be implemented in patients with prostate cancer to reduce the chances of a cardio-related adverse-event.